Home' Australian Pharmacist : Australian Pharmacist June 2013 Contents Australian Pharmacist June 2013 I © Pharmaceutical Society of Australia Ltd.
Submit your answers online before
1 August 2013 at www.psa.org.au
and receive automatic feedback, or NZ
members can fax/mail to:
NZCP CPD answers,
PO Box 11 640, Wellington
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions,
4 out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. Indacaterol is a bronchodilator drug
that offers advantages over existing
beta agonist bronchodilators
a) it is ultra long-acting, so can be used
once a day.
b) it does not have beta agonist
c) it can be used in both asthma
d) it can be used as an anti-inflammatory
2. Indacaterol is marketed for use with
a dry powder inhaler device called
a Breezhaler. Notable points about
the Breezhaler include:
a) it is a device that requires coordination
between actuation and inhalation.
b) it requires no inspiratory effort.
c) it is an automated delivery device.
d) it requires inspiratory effort in the
range of 60L/min, which most people
in stable COPD can achieve.
3. A new strategy for drugs in COPD
includes developing dimers –
where two drug classes are pegged
on the same molecule. Current
dimers in the clinical trial stage
for COPD include:
a) long-acting beta agonist and short-
acting beta agonist on same molecule.
b) long-acting antimuscarinic and
short-acting antimuscarinic on
c) long-acting beta agonist and
long-acting antimuscarinic agent on
the same molecule.
d) long-acting beta agonist and
short-acting antimuscarinic agent on
the same molecule.
4. Other roles that pharmacists can
play to improve COPD outcomes is
to encourage vaccinations. Which of
the following is true for vaccination
related evidence in COPD?
a) Influenza vaccinations can reduce the
rate of exacerbations, hospitalisations
b) Pneumococcal vaccinations can
reduce the rate of exacerbations,
hospitalisations and death.
c) Anti-smoking vaccines can reduce the
rate of exacerbations, hospitalisations
d) Pertussis vaccines can reduce the rate
of exacerbations, hospitalisations
1. Australian Institute of Health and Welfare. Australia’s health
2012. Australia’s health series no.13. Cat. no. AUS 156. Canberra:
AIHW; 2012. P. 285.
2. Toelle B, Xuan W, Bird T, et al. Respiratory symptoms and illness
in older Australians: the Burden of Obstructive Lung Disease
(BOLD) study. MJA 2013;198(3):144–8.
3. Australian Institute of Health and Welfare. Asthma, chronic
obstructive pulmonary disease and other respiratory diseases
in Australia. Asthma series. Cat. no. ACM 20. Canberra: AIHW;
4. Lung Foundation. The COPDX plan. At: www.copdx.org.au/
5. Pharmaceutical Benefits Scheme. Online Schedule. At: www.
6. Australian Medicines Handbook. Respiratory drugs. AMH; 2013.
7. Balint B, Watz H, Amos C, et al. Onset of action of indacaterol
in patients with COPD: Comparison with salbutamol and
salmeterolfluticasone. Int J Chron Obstruct Pulmon Dis
8. McKeage K. Indacaterol: a review of its use as maintenance
therapy in patients with chronic obstructive pulmonary
disease. Drugs 2012;72(4):543–63 . DOI: 10.2165/11208490-
9. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic
obstructive pulmonary disease: a systematic review and meta-
analysis of randomized placebo-controlled trials. BMC Pulm
10. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of
dyspnea. Contents, interobserver agreement, and physiologic
correlates of two new clinical indexes. Chest 1984;85:751–8.
11. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns
of response of the transition dyspnea index. J Clin Epidemiol
12. Cazzola M, Page CP, Rogliani P, et al. Beta2-agonist therapy in
lung disease. Am J Respir Crit Care Med 2013;187(7):690–6 .
13. Fink JB, Colice GL, Hodder R. Inhaler devices for patients with
COPD. COPD 2013 Mar 28.
14. Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule
based dry powder inhaler for the delivery of indacaterol. Curr
Med Res Opin 2010;26(11):2527–33 .
15. Reddel HK, Bosnic-Anticevich SZ, Amour CL, et al. Pharmacist
interventions in asthma. Eur Respir J 2008;32(3):812.
16. Cazzola M, Rogliani P, Ruggeri P, et al. Chronic treatment with
indacaterol and airway response to salbutamol in stable COPD.
Respir Med 2013. DOI:pii: S0954-6111(13)00057-7 . 10.1016/j.
17. Decramer ML, Hanania NA, Lötvall JO, et al. The safety of
long-acting beta2-agonists in the treatment of stable chronic
obstructive pulmonary disease. Int J Chron Obstruct Pulmon
18. Ngkelo A, Adcock IM. New treatments for COPD. Curr Opin
Pharmacol 2013. DOI:pii: S1471-4892(13)00048-9 .
19. Yohannes AM, Connolly MJ, Hanania NA. Ten years of
tiotropium: clinical impact and patient perspectives. Int J
Chron Obstruct Pulmon Dis 2013;8:117–25 .
20. Australian Centre for Asthma Monitoring. Asthma in Australia
2011. AIHW Asthma Series no. 4 . Cat.no. ACM 22. AIHW:
21. Ta M, George J. Management of chronic obstructive
pulmonary disease in Australia after the publication of national
guidelines. Intern Med J 2011;41(3):263–70.
22. Rand CS. Patient adherence with COPD therapy. Eur Respir J
23. Macnee W. Systemic inflammatory biomarkers and co-
morbidities of chronic obstructive pulmonary disease. Ann
Med 2013;45(3):291-300. DOI: 10.3109/07853890.2012.732703.
Links Archive Australian Pharmacist May 2013 Australian Pharmacist July 2013 Navigation Previous Page Next Page